Notably, the same study revealed that Gal-3 is highly expressed in advanced stages of ovarian cancer and promotes tumor growth in xenograft models, suggesting that targeting Gal-3 could improve ovarian cancer therapy [121]. Here, LGALS3 is linked to ovarian carcinoma.